A story on HispanicBusiness.com says pharmaceutical companies Merck and Pfizer, ordinarily rivals, are teaming up to develop a new medicine for type 2 diabetes.
Merck is paying $60 million up front for the rights to co-develop Pfizer’s diabetes drug called ertugliflozin, which is currently in late-stage development. Merck will also get the right to market ertugliflozin separately or in combination with its own diabetes treatment.
But recent health concerns have cropped up ...
continue reading...
According to a story in the International Business Times, a batch of baby powder from a Johnson & Johnson plant in India was found to be contaminated with a carcinogen. That finding prompted the Food and Drug Administration to cancel Johnson & Johnson’s license to manufacture the powder at that plant.
According to an NBC News blog, the discovery of a new hormone that makes the cells destroyed by diabetes has enormous potential for treating the disease.
A story in Forbes describes Johnson & Johnson’s new global branding campaign, which will cost the medical products giant an estimated $20 million to $30 million for the remainder of the year.
Scientists have developed a new method to make an artificial kidney that functions in rats, intensifying a race among several laboratories to create a replacement organ that may someday be used for humans.
The Wall Street Journal says a dramatic sales drop in Pfizer’s anti-cholesterol medication Lipitor was behind the company’s nine percent revenue decline for the first quarter, which was worse than expected and lowered the company’s full-year outlook.
